Scans

Tools

Home

Charts

Watchlist

Products

Aayush Wellness Ltd

AAYUSH

BSE

₹25.34+0.24%19 Oct 2026

Reports

Trading

Aayush Wellness Ltd

AAYUSH

BSE

₹25.34

+0.24%

19 Oct 2026

SOICxStockScans Reports

Ask AI

Trading

Indices

Business Overview: What the company does, in plain English.Growth Catalysts: The forward growth drivers and triggers.

Aayush Wellness is a health and wellness company built on a single, sweeping pivot - it was a Basmati rice exporter for decades until 2024, when it rebranded and redirected everything toward herbal alternatives, supplements, diagnostics and wellness services. The recurring approach is to spot a large, often troubled consumer habit - chewing tobacco, poor sleep, undiagnosed conditions - and offer an Indian-rooted, Ayurvedic-informed product or service that is easy to access and priced for mass adoption.

Business segments

A single consumer health platform expressed through four product-and-service lines - a herbal alternative to tobacco, a growing shelf of nutraceutical gummies and tablets, a network of diagnostic kiosks and digital health tools, and an early-stage wellness tourism plan - all built on the same asset-light, omni-channel distribution logic.

1. Herbal Pan Masala: the legal alternative to a 46,000-crore habit

A tobacco-free, supari-free chew that mimics the taste of traditional pan masala and gutkha, sold in sachets at the same price point and the same kirana counters - a swap, not a sacrifice.

Designed for the 27.49-crore tobacco user base - the product is formulated with Ayurvedic ingredients as a non-addictive, spit-free alternative, targeting the nearly 29% of smokeless tobacco users who already say they want to quit.
Priced to remove the cost excuse - launched at roughly Rs. 7 per serving and later extended with a Rs. 10 sachet in three flavours (Pan Masala, Gutka, and Tobacco+Pan Masala), so that switching does not stretch the daily wallet of a mass-market consumer.
Sold where the old habit was bought - offline distribution runs through general trade, kirana stores and pan shops, while online it sits on Flipkart and on Blinkit for rapid hyperlocal delivery, putting a safer option within the same reach as the original product.
Regulatory crackdowns open the door - when Maharashtra invoked the organised-crime act against illegal gutkha syndicates in mid-2026, the company flagged it as a direct growth lever that pushes consumers toward a legal, tobacco-free alternative and shrinks the unorganised competition.

2. Nutraceuticals: supplements built for India’s specific deficiencies

A portfolio of gummies, capsules and tablets that targets conditions with large, measurable prevalence - poor sleep, nutritional gaps, metabolic disorders - and reaches buyers through quick-commerce, marketplaces and the company’s own site.

Launched with a sleep problem half the country shares - the first product, Dreamy Sleep Gummies, addressed the finding that 49% of Indians struggle to fall asleep at least three times a week, offering a convenient nutraceutical solution.
Built outward from beauty to brain to blood sugar - subsequent launches included Beauty Vitamins Gummies for skin and hair, Brain Fuel Capsules for cognition, Immunity Booster Tablets, Liver Detox Tablets, and Dia Shield Tablets for the 23-crore-plus Indians affected by metabolic conditions.
Omni-channel from day one - products are listed on Amazon.in with 24-48 hour delivery, on the company’s own direct-to-consumer website, on Blinkit for quick-commerce, and in offline retail stores, so the purchase path matches how urban India already shops.
Export order validates the formulation - a US$ 3 million order from a Singapore distributor, covering effervescent tablets, marine collagen, probiotics and super-greens powders, opened the door to a Southeast Asian supplements market projected to cross a billion dollars by 2033.

3. Preventive Healthcare Services: a diagnostic kiosk in every neighbourhood

Physical health centres built around an AI-enabled kiosk that runs 59 tests in under three minutes, backed by teleconsultation and a digital lab platform - healthcare delivery without the heavy hospital build.

The health ATM is the front door - the first centre in Virar, Mumbai, houses a kiosk that screens blood, sugar, urine, haemoglobin, lipids, skin, eye and cancer risk test in 2-3 minutes, creates a digital health record and connects to a doctor via telemedicine, inspired by the E-Sanjeevani National Telemedicine Service.
Services wrap around the kiosk - each centre also offers online consultations, hospitalisation assistance, insurance claims processing, vaccinations, mental wellness programmes, home care coordination and patient transport, making it a one-stop primary-care touchpoint.
Digital platforms extend the reach - the “Aayush Health” app and “Aayush Labs” website add teleconsultation, home sample collection, digital prescriptions and ABHA ID creation, operating on an asset-light model with a central lab for quality control rather than a chain of owned labs.
Equipment sourced through a joint venture, not built - a lifetime agreement with Healthrashi Nextgen India gives Aayush access to AI kiosks, mobile clinics and automated diagnostic platforms at optimised cost, which it then deploys under its own brand without taking any equity stake in the supplier.

4. Wellness Tourism: a planned bet on India’s 21-billion-dollar retreat market

An approved but not-yet-operational plan to build wellness retreats offering yoga, Ayurveda and spa therapies, developed with government and private partners.

Board approval with a Rs. 30 crore envelope - the diversification was greenlit in December 2024 with an investment plan spread over two years, targeting therapeutic yoga, guided meditation, Ayurvedic treatments, spa therapies and nutritional counselling.
Partnership-led, not solo-built - the company intends to work with government agencies, tourism promotion boards and private businesses to establish the centres, rather than acquiring and developing real estate entirely on its own.

Group structure and partners

A lean holding company with five wholly owned subsidiaries - most still nascent - and a partnership model that supplies the hardware and the last-mile reach without tying up capital in equity stakes.

Five wholly owned subsidiaries sit under Aayush Wellness: Aayush Worldwide (exports), Aayush Healthsciences, Aayush Labs (diagnostics aggregator), Aayush Ventures (software) and Aayush International Pte. Ltd. in Singapore (Southeast Asian market entry) - though as of the latest filings, the first two had not yet generated any turnover.
The joint venture with Healthrashi Nextgen India supplies medical equipment - AI kiosks, mobile clinics, diagnostic platforms - under a lifetime agreement with no equity exchanged and no board seats, keeping the arrangement purely commercial.
The Blinkit partnership puts herbal pan masala and nutraceuticals onto a quick-commerce platform with zero shareholding on either side, adding hyperlocal delivery without building a logistics fleet.

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Price

Charts

Documents

Edit Ratios

Mkt Cap

Market Capitalization

₹123Cr

Close Price

₹25.34

Industry

Trading

Price To Earnings

28.80

Price To Sales

0.74

Revenue

₹166Cr

Rev Gr TTM

Revenue Growth TTM

95.50%

PAT Gr TTM

PAT Growth TTM

-0.47%

Consolidated

Standalone

Numbers

Percentage

Quarter	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	0	0	11	14	26	22	23	40	45	48	33
Growth YoY Revenue Growth YoY%							104.2	179.5	73.7	116.6	46.3
Expenses ExpensesCr	0	0	11	13	25	21	22	39	44	48	32
Operating Profit Operating ProfitCr	0	0	0	1	1	1	1	1	0	0	1
OPM OPM%			2.1	6.4	4.3	5.3	2.3	1.4	0.9	0.7	2.4
Other Income Other IncomeCr	0	0	0	0	0	0	1	1	1	1	1
Interest Expense Interest ExpenseCr	0	0	0	0	0	0	0	0	0	0	0
Depreciation DepreciationCr	0	0	0	0	0	0	0	0	0	0	0
PBT PBTCr	0	0	0	1	1	1	1	1	1	1	1
Tax TaxCr	0	0	0	0	0	0	0	0	0	0	0
PAT PATCr	0	0	0	1	1	1	1	1	1	1	1
Growth YoY PAT Growth YoY%					3,533.3	541.2	364.0	31.5	-3.7	-48.6	22.4
NPM NPM%			2.3	6.4	4.3	4.9	5.1	3.0	2.4	1.2	4.3
EPS EPS₹	0.0	0.0	0.1	0.2	0.2	0.2	0.2	0.3	0.2	0.1	0.3

Quarter	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	0	0	11	14	26	22	23	40	45	48	33
Growth YoY Revenue Growth YoY%							104.2	179.5	73.7	116.6	46.3
Expenses ExpensesCr	0	0	11	13	25	21	22	39	44	48	32
Operating Profit Operating ProfitCr	0	0	0	1	1	1	1	1	0	0	1
OPM OPM%			2.1	6.4	4.3	5.3	2.3	1.4	0.9	0.7	2.4
Other Income Other IncomeCr	0	0	0	0	0	0	1	1	1	1	1
Interest Expense Interest ExpenseCr	0	0	0	0	0	0	0	0	0	0	0
Depreciation DepreciationCr	0	0	0	0	0	0	0	0	0	0	0
PBT PBTCr	0	0	0	1	1	1	1	1	1	1	1
Tax TaxCr	0	0	0	0	0	0	0	0	0	0	0
PAT PATCr	0	0	0	1	1	1	1	1	1	1	1
Growth YoY PAT Growth YoY%					3,533.3	541.2	364.0	31.5	-3.7	-48.6	22.4
NPM NPM%			2.3	6.4	4.3	4.9	5.1	3.0	2.4	1.2	4.3
EPS EPS₹	0.0	0.0	0.1	0.2	0.2	0.2	0.2	0.3	0.2	0.1	0.3

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	1	73	155	166
Growth Revenue Growth%		12,063.5	112.0	95.5
Expenses ExpensesCr	0	70	154	164
Operating Profit Operating ProfitCr	0	3	2	2
OPM OPM%	59.4	4.5	1.2	1.3
Other Income Other IncomeCr	0	0	3	3
Interest Expense Interest ExpenseCr	0	0	0	0
Depreciation DepreciationCr	0	0	0	0
PBT PBTCr	1	3	4	5
Tax TaxCr	0	0	0	0
PAT PATCr	1	3	4	4
Growth PAT Growth%		488.6	18.3	-0.5
NPM NPM%	94.8	4.6	2.6	2.5
EPS EPS₹	0.1	0.7	0.8	0.9

Financial Year	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	1	73	155	166
Growth Revenue Growth%		12,063.5	112.0	95.5
Expenses ExpensesCr	0	70	154	164
Operating Profit Operating ProfitCr	0	3	2	2
OPM OPM%	59.4	4.5	1.2	1.3
Other Income Other IncomeCr	0	0	3	3
Interest Expense Interest ExpenseCr	0	0	0	0
Depreciation DepreciationCr	0	0	0	0
PBT PBTCr	1	3	4	5
Tax TaxCr	0	0	0	0
PAT PATCr	1	3	4	4
Growth PAT Growth%		488.6	18.3	-0.5
NPM NPM%	94.8	4.6	2.6	2.5
EPS EPS₹	0.1	0.7	0.8	0.9

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	3	5	5
Reserves ReservesCr	2	3	7
Current Liabilities Current LiabilitiesCr	0	0	1
Non Current Liabilities Non Current LiabilitiesCr	0	0	5
Total Liabilities Total LiabilitiesCr	5	9	18
Current Assets Current AssetsCr	1	1	7
Non Current Assets Non Current AssetsCr	4	7	10
Total Assets Total AssetsCr	5	9	18

Financial Year	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	3	5	5
Reserves ReservesCr	2	3	7
Current Liabilities Current LiabilitiesCr	0	0	1
Non Current Liabilities Non Current LiabilitiesCr	0	0	5
Total Liabilities Total LiabilitiesCr	5	9	18
Current Assets Current AssetsCr	1	1	7
Non Current Assets Non Current AssetsCr	4	7	10
Total Assets Total AssetsCr	5	9	18

Consolidated

Standalone

Financial Year	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	-1	0	-5
Investing Cash Flow Investing Cash FlowCr	0	0	3
Financing Cash Flow Financing Cash FlowCr	0	0	5
Net Cash Flow Net Cash FlowCr	-1	0	2
Free Cash Flow Free Cash FlowCr	-1	0
CFO To PAT CFO To PAT%	-99.3	11.3	-136.4
CFO To EBITDA CFO To EBITDA%	-158.6	11.4	-296.7

Financial Year	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	-1	0	-5
Investing Cash Flow Investing Cash FlowCr	0	0	3
Financing Cash Flow Financing Cash FlowCr	0	0	5
Net Cash Flow Net Cash FlowCr	-1	0	2
Free Cash Flow Free Cash FlowCr	-1	0
CFO To PAT CFO To PAT%	-99.3	11.3	-136.4
CFO To EBITDA CFO To EBITDA%	-158.6	11.4	-296.7

Consolidated

Standalone

Financial Year	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	57	273	135	123
Price To Earnings Price To Earnings	99.9	81.3	33.8	28.8
Price To Sales Price To Sales	95.0	3.7	0.9	0.7
Price To Book Price To Book	11.6	33.0	11.0	10.1
EV To EBITDA EV To EBITDA	159.2	81.6	75.0	59.8
Profitability Ratios Profitability Ratios
GPM GPM%	99.2	6.1
OPM OPM%	59.4	4.5	1.2	1.3
NPM NPM%	94.8	4.6	2.6	2.5
ROCE ROCE%	12.1	40.5	25.9	25.9
ROE ROE%	11.6	40.6	32.5	32.5
ROA ROA%	11.4	38.9	22.7	22.7
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Financial Year	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	57	273	135	123
Price To Earnings Price To Earnings	99.9	81.3	33.8	28.8
Price To Sales Price To Sales	95.0	3.7	0.9	0.7
Price To Book Price To Book	11.6	33.0	11.0	10.1
EV To EBITDA EV To EBITDA	159.2	81.6	75.0	59.8
Profitability Ratios Profitability Ratios
GPM GPM%	99.2	6.1
OPM OPM%	59.4	4.5	1.2	1.3
NPM NPM%	94.8	4.6	2.6	2.5
ROCE ROCE%	12.1	40.5	25.9	25.9
ROE ROE%	11.6	40.6	32.5	32.5
ROA ROA%	11.4	38.9	22.7	22.7
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

	FRESITA	GVPTECH	FRETAIL	AAYUSH	OSIAJEE	PRAMARA	GRAVITY
Market CapitalizationMkt CapCr	137	124	124	123	122	121	120
Close PriceClose₹	153.05	6.77	2.28	25.34	225.15	87.00	15.43
IndustryIndustry	Trading	Trading	Trading	Trading	Trading	Trading	Trading
Price To EarningsPE	5.18			28.80	30.43	12.08	0.80
Price To SalesPS	7.55	51.10	0.01	0.74	16.89	1.08	0.50
RevenueRevenueCr	18	2	8,615	166	7	112	239
Revenue Growth TTMRev Gr TTM%	-48.2%	-61.3%	-1.9%	95.5%	0.3%		58,239.0%
PAT Growth TTMPAT Gr TTM%	812.8%	-13,325.4%	-71.2%	-0.5%	22.2%		1,568.0%

	FRESITA	GVPTECH	FRETAIL	AAYUSH	OSIAJEE	PRAMARA	GRAVITY
Market CapitalizationMkt CapCr	137	124	124	123	122	121	120
Close PriceClose₹	153.05	6.77	2.28	25.34	225.15	87.00	15.43
IndustryIndustry	Trading	Trading	Trading	Trading	Trading	Trading	Trading
Price To EarningsPE	5.18			28.80	30.43	12.08	0.80
Price To SalesPS	7.55	51.10	0.01	0.74	16.89	1.08	0.50
RevenueRevenueCr	18	2	8,615	166	7	112	239
Revenue Growth TTMRev Gr TTM%	-48.2%	-61.3%	-1.9%	95.5%	0.3%		58,239.0%
PAT Growth TTMPAT Gr TTM%	812.8%	-13,325.4%	-71.2%	-0.5%	22.2%		1,568.0%

FY2026

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2026

Jun 26